Carboplatin-Paclitaxel vs Other Platinum-Doublets in Advanced NSCLCCarboplatin-Paclitaxel vs Other Platinum-Doublets in Advanced NSCLC
In elderly patients with advanced non-small cell lung cancer and squamous cell histology, carboplatin plus paclitaxel yields slightly better survival than carboplatin with either gemcitabine or docetaxel. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Health | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma | Taxotere